Key points are not available for this paper at this time.
The shift toward decentralized cancer care has accelerated the demand for innovative technologies that enable continuous, remote monitoring of patients undergoing chemotherapy. Wearable biosensors have emerged as a promising solution, offering real-time tracking of physiological and biochemical markers critical to chemotherapy management. This review explores the integration of wearable biosensors into remote chemotherapy monitoring, examining their technological foundations, clinical applications, and impact on patient outcomes. It highlights how these devices enhance adherence, detect adverse effects early, and support timely clinical decisions in outpatient and home-based settings. Additionally, the paper addresses key implementation challenges, including technical limitations, patient usability, and regulatory considerations. Finally, it discusses future directions in sensor development, artificial intelligence integration, and policy adaptation to support scalable, personalized cancer care. Wearable biosensor technology holds transformative potential to redefine chemotherapy delivery within decentralized care models.
Atalor et al. (Tue,) studied this question.